A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma

Local Institution - 301, New York

Local Institution - 203, Berlin

Local Institution - 112, Marseille

Local Institution - 310, Buffalo

Local Institution - 304, Philadelphia

Local Institution - 209, Hamburg

Local Institution - 106, Dijon

Local Institution - 109, Toulouse

Local Institution - 108, Pessac

Local Institution - 107, Montpellier

Local Institution - 101, Rennes

Local Institution - 207, Göttingen

Local Institution - 312, Nashville

Local Institution - 302, Cleveland

Local Institution - 206, Essen

Local Institution - 204, Cologne

Local Institution - 116, Vandœuvre-lès-Nancy

Local Institution - 113, Lille

Local Institution - 311, Chicago

Local Institution - 115, Strasbourg

Local Institution - 210, Heidelberg

Local Institution - 103, Pierre-Bénite

Local Institution - 201, Stuttgart

Local Institution - 114, Paris

Local Institution - 102, Paris

Local Institution - 303, Houston

Local Institution - 105, Rouen

Local Institution - 202, Freiburg im Breisgau

Local Institution - 305, Aurora

Local Institution - 205, Ulm

Local Institution - 110, Saint-Cloud

Local Institution - 307, Stanford

Local Institution - 306, Seattle

Local Institution - 308, Tampa

Local Institution - 314, Boston

Local Institution - 313, Boston

Local Institution - 316, St Louis

Local Institution - 315, New Brunswick

Local Institution - 309, Columbus

Local Institution - 111, Nice

Local Institution - 104, Nantes

Local Institution - 208, Chemnitz